Article ID: 714657

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.

Article ID: 714361

Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.

Article ID: 713799

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

Article ID: 712819

A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.

Article ID: 711418

In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.

Article ID: 710507

A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.

Article ID: 710513

New research from Roswell Park Comprehensive Cancer Center reports that timing of radiation treatments can significantly reduce severity of mucositis and its related impacts.

Article ID: 710506

Final results from the first U.S. clinical study of CIMAvax-EGF show that this Cuban immunotherapy is safe and showed promising efficacy as part of a treatment combination with nivolumab in patients with advanced non-small cell lung cancer.

Article ID: 708506

Several Roswell Park Comprehensive Cancer Center experts were invited to highlight research and best practices during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.

Article ID: 706513

Roswell Park Comprehensive Cancer Center has been recognized as one of America’s Best Employers for Diversity 2019. The Buffalo cancer center was ranked 67th among 500 employers and 8th among the 30 employers within the health care sector to be named to the list, which is based on employee surveys.